Physician profile
Kimberly E Lott
NPI 1306802236
$6,766.06
in general payments reported to CMS, 2019-2025
35 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,437 · 2022: $1,136 · 2023: $1,287 · 2024: $1,294 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,492.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,117.99 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $687.83 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $495.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $314.49 | 2022-2025 | |
| Amgen INC. | $299.18 | 2021-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $295.98 | 2021-2023 | Seglentis, Livalo |
| Abbvie INC. | $269.77 | 2021-2025 | |
| Lilly USA, LLC | $246.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $214.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $203.01 | 2021-2023 | Belsomra, Steglatro, Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $149.86 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $104.50 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $86.51 | 2021-2024 | Xarelto |
| Abbott Laboratories | $74.22 | 2023-2024 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $68.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.66 | 2024-2025 | Xifaxan |
| Ibsa Pharma INC. | $60.65 | 2021-2023 | Tirosint, Licart |
| Dexcom, INC. | $58.62 | 2021-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $51.48 | 2022-2025 | Opdivo, Eliquis |
| Eisai INC. | $49.94 | 2021-2022 | |
| Corcept Therapeutics | $47.27 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $44.29 | 2022-2023 | |
| Daiichi Sankyo INC. | $35.18 | 2021-2022 | |
| Astellas Pharma US INC | $33.06 | 2023-2024 | Myrbetriq, Veozah |
| Xeris Pharmaceuticals, INC. | $32.12 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $24.64 | 2023 | Gemtesa |
| Quidel Corporation | $23.06 | 2023 | |
| Exact Sciences Corporation | $18.06 | 2025 | The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $18.02 | 2025 | Xyosted |
| Axsome Therapeutics, INC. | $17.95 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $17.87 | 2022 | |
| Medtronic, INC. | $16.48 | 2023 | Minimed 780g |
| Verona Pharma, INC. | $15.18 | 2025 | Ohtuvayre |
| Fresenius Kabi USA, LLC | $13.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.